Piper Sandler initiates coverage on Abbott with an Overweight rating, citing its diversified business model, strong medtech ...

Let's not forget about Abbott Laboratories' impressive streak of 52 consecutive annual dividend increases, which also makes ...

Texas Gov. Greg Abbott swore in the first judges for the state’s new Business Court at the Texas A&M University School of Law ...

Fintel reports that on September 19, 2024, Piper Sandler initiated coverage of Abbott Laboratories (NYSE:ABT) with a ...

Abbott's strong innovation pipeline, including advancements in CGM systems, supports its market share gains and growth ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Buy rating on Abbott Laboratories (ABT). Adam Maeder has given his Buy rating ...

The veteran Labour MP says she felt at risk after Frank Hester’s comments and expected more support from the Labour leader ...

Cardio.ai announced a collaboration with Abbott (NYSE:ABT) to develop AI applications for the medtech giant's imaging ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), ...

Some people are facing delays in filling prescriptions for the glucose sensor. Abbott expects to resolve the problem soon.

Abbott Laboratories' diabetes care segment recently added new products to its lineup. It should remain one of the company's key growth drivers over the long run. There are other good reasons to ...

Abbott Laboratories closed $4.01 short of its 52-week high ($121.64), which the company reached on March 8th.